GenSight Biologics will participate to the 2019 North American Neuro-Ophthalmology Society (NANOS) 45thAnnual Meeting at the Red Rock Casino, Resort & Spa, Las Vegas, Nevada.

The 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented by Dr. Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology at the Emory University School of Medicine in Atlanta, GA, USA. Dr. Newman is an International Principal Investigator and Site Principal Investigator of the REVERSE trial. Widely recognized as one of the leading authorities on Leber Hereditary Optic Neuropathy (LHON), Dr. Newman has been integral to defining and describing LHON pathophysiology and clinical declarations.

rAAV2/2-ND4 Treatment of Leber Hereditary Optic Neuropathy: 72-Week Data from the REVERSE Phase III Clinical Trial presented by Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology, Emory University School of Medicine, Atlanta, GA

  • Scientific Platform Session III, Red Rock Ballroom
  • Tuesday, March 19, 10:30 am – 10:45 am PDT